Background: The development of hemolytic alloantibodies and erythrocyte autoantibodies
complicates transfusion therapy in thalassemia patients. Methods: The frequency, causes …

Life-long red blood TRANSFUSION remains the main treatment for severe THALASSEMIA.
The development of hemolytic alloantibodies and erythrocyte autoantibodies complicated …

Life long red blood transfusion remains the main treatment for β thalassemia major patients.
The development of alloantibodies complicates transfusion therapy in thalassemia patients …

Background: Patients with thalassemia major are clinically dependent on red blood cell
(RBC) transfusions. Performing multiple transfusions increase the risk of transfusion-related …

The development of hemolytic erythrocyte alloantibodies and autoantibodies complicates
transfusion therapy in thalassemia patients. These antibodies ultimately increase the need …

Background: The development of anti-red blood cell antibodies (both allo-and
autoantibodies) remains a major problem in thalassemia major patients. We studied the …

Background: Thalassemia is a common hemoglobin disorder in Iran and one of the major
public health problems. Although blood transfusions are lifesavers for thalassemia patients …

Background: The development of anti-red blood cell alloantibodies remains a major problem
in transfusion of blood in thalassemia major patients. Also, Autoantibodies can result in …

The development of erythrocyte alloantibodies complicates transfusion therapy in β
thalassemia major patients. These antibodies increase the need for blood and intensify …

Objective: To provide frequency and distribution pattern of various types of irregular red cell
alloantibodies in patients with thalassemia major. Methods: This is a descriptive study …